Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2019

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Gilde Healthcare exits occupational health provider BlijWerkt to Mentha Capital

December 18, 2019 – Utrecht (the Netherlands) – Gilde Healthcare today announced it has sold its majority stake in occupational health provider BlijWerkt to Mentha Capital, subject to approval by the Dutch Healthcare Authority. Led by Gilde, BlijWerkt has become a national player and challenger to the…

Related to: BlijWerkt

Lumeon partners with Medtronic on value-based care

December 4, 2019 – Utrecht (the Netherlands) and London, (UK) – Lumeon, the leader in Care Pathway Management (CPM), today announced that it has entered a strategic partnership with Medtronic, a global leader in medical technology, services, and solutions, that will support Medtronic’s European healthcare…

Related to: Lumeon

Axonics® raises $110 million via Public Offering of Common Stock

November 21, 2019 – Irvine, CA (US) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today…

Related to: Axonics Modulation Technologies

Axonics® announces U.S. FDA approval for its sacral neuromodulation system for urinary clinical indications

November 14, 2019 – Irvine, CA (US) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced…

Related to: Axonics Modulation Technologies

Sanifit announces positive Phase 2b data in cardiovascular calcification

October 30, 2019 – Utrecht (The Netherlands), Palma (Spain) and San Diego (US) – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage…

Related to: Sanifit

Nyxoah publishes positive clinical data

October 28, 2019 – Utrecht (The Netherlands) and Mont-Saint-Guibert (Belgium) – Nyxoah S.A., a healthtech company focused on the development of innovative solutions and services for sleep related disorders, announced today the publication of data from the BLAST OSA (BiLAteral Hypoglossal Nerve Stimulation…

Related to: Nyxoah

Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting

October 3, 2019 – Durable Outcomes Highlighted in Plenary Session Presentation; Expanding on Positive Topline Data Released in August More than 350 Physicians Attended a Symposium Highlighting Hands-on Physician Experience with the Recently FDA-Approved Axonics r-SNM® System1  IRVINE, Calif.— Axonics…

Related to: Axonics Modulation Technologies

Acacia Pharma announces new BARHEMSYS® PDUFA date of 26 february 2020

September 26, 2019 – Utrecht (The Netherlands) and Cambridge (Massachusetts) – Gilde Healthcare company Acacia Pharma (BRU:ACPH), a pharmaceutical company developing and commercializing hospital products for US and international markets, announces that the US Food and Drug Administration (FDA) has accepted…

Related to: Acacia Pharma

Axonics receives FDA approval for neurostimulator to treat fecal incontinence

September 9, 2019 – Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare company Axonics, a medical technology company that commercializes a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced the…

Related to: Axonics Modulation Technologies

Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension

September 3, 2019 – Data Provide Preliminary Evidence of Efficacy of the Investigational Peregrine System Kit SAN JOSE, Calif. and PARIS – Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced 12-month results from the Peregrine Post-Market…

Related to: Ablative Solutions

CVRx obtains FDA approval for heart failure neuromodulation device

August 19, 2019 – Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare company CVRx, Inc., announces today that it received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO device for heart failure in the United States.…

Related to: CVRx

Gilde Healthcare announces acquisition of Breath Therapeutics by Zambon for up to €500 million

July 25, 2019 – Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare today announced it has sold its shareholding in portfolio company Breath Therapeutics to Zambon, an Italian multinational pharmaceutical company. Zambon will pay an initial consideration of €140 million with a…

AM-Pharma Raises Record Financing of €116m [$133m] for Phase III Trial in Acute Kidney Injury

July 16, 2019 – Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial…

Related to: AM-Pharma

Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer

July 11, 2019 – Veteran Leader Brings Extensive Experience from Both Pharma and Device Industries San Jose, Calif., US - Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced that Kate Rumrill has been appointed as the new President and…

Related to: Ablative Solutions

Acacia Pharma plans to resubmit the BARHEMSYS® NDA in Q3 2019

July 8, 2019 – Cambridge, UK and Indianapolis, US - Acacia Pharma, a pharmaceutical company developing and commercialising hospital products for US and international markets, announces receipt of the official Type A meeting minutes from the US Food and Drug Administration (“FDA”) relating to the…

Related to: Acacia Pharma

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer

July 2, 2019 – IRVINE, Calif., /PRNewswire/ -- Inari Medical, Inc. announced today that the company has appointed Thomas M. Tu, M.D. as Chief Medical Officer. Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism (PE). He was the lead author in the publication of the…

Related to: Inari Medical, Inc.

Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise

June 26, 2019 – Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis Round led by Spanish investor Caixa Capital Risc Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to…

Related to: Sanifit

Gilde Healthcare co-leads $37M financing of Vesper Medical to complete development of its Duo Venous Stent System

June 4, 2019 – Utrecht (The Netherlands), Cambridge (United States) - Gilde Healthcare today announces its investment in Vesper Medical, Inc. (Wayne, PA), a developer of medical devices for minimally invasive peripheral vascular procedures. Gilde Healthcare led the $37 million financing together…

Related to: Vesper Medical, Inc.

QIAstat-Dx gains 510(k) clearance by FDA, triggering milestone payment for Gilde Healthcare

May 20, 2019 – Utrecht, The Netherlands - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced 510(k) clearance of its QIAstat-Dx syndromic testing system by the U.S. Food and Drug Administration. The regulatory approval will trigger a milestone payment to Gilde Healthcare which…

Related to: STAT-Dx QIAGEN

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome

March 26, 2019 – Phase 3 BOSTON clinical studies will evaluate Liposomal Cyclosporine A for Inhalation (L CsA i), the first potential therapy for Bronchiolitis Obliterans Syndrome (BOS) BOS is a devastating lung disease with high mortality affecting over 30,000 people worldwide following lung or…

Related to: Breath Therapeutics

Nyxoah receives European CE Mark approval for the Genio™ system to treat sleep apnea

March 19, 2019 – Utrecht, The Netherlands and Mont-Saint-Guibert, Belgium – Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio™ system in Europe.…

Related to: Nyxoah

Gilde Healthcare acquires healthcare food supplier Eetgemak from Value8

March 11, 2019 – Gilde Healthcare’s investment allows Eetgemak to realize new growth plans, including expansion into Belgium Utrecht and Frankfurt - Gilde Healthcare, the European specialist investor in healthcare, acquires a majority stake in Eetgemak from stock listed investment firm Value8.…

Related to: Eetgemak

Gilde Healthcare raises €200 million for new private equity fund

March 7, 2019 – Targeting lower mid-market healthcare investments in the Benelux and DACH regions Utrecht (the Netherlands) and Frankfurt (Germany) – Gilde Healthcare, the European specialist investor in healthcare, today announces that it has raised €200 million for its third private equity fund,…

Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update

March 5, 2019 – IRVINE, CA – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial…

Related to: Axonics Modulation Technologies

Gilde Healthcare leads EUR 20M Series A financing round of Calypso Biotech

February 21, 2019 – Utrecht, The Netherlands and Boston, US - Calypso Biotech (Amsterdam, The Netherlands), an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing led by Gilde Healthcare and Inkef Capital. They…

Related to: Calypso Biotech B.V.

Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System

February 14, 2019 – Irvine, CA – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission…

Related to: Axonics Modulation Technologies

Acacia Pharma reports positive cardiac safety data for BARHEMSYS™

January 22, 2019 – Cambridge, UK and Indianapolis, US - Acacia Pharma (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™, its anti-emetic currently under FDA review for the management of post-operative nausea & vomiting (PONV).   The study did not find a significant risk for heart…

Related to: Acacia Pharma

Gilde Healthcare leads USD 77 million financing round of hypertension company Ablative Solutions

January 3, 2019 – Ablative Solutions today announced the first close of its USD 77 million Series D funding round. The round was led by Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor.

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy